دورية أكاديمية
أعرض في EDS

Inhibitory evaluation of Curculigo latifolia on α-glucosidase, DPP (IV) and in vitro studies in antidiabetic with molecular docking relevance to type 2 diabetes mellitus.

التفاصيل البيبلوغرافية
العنوان: Inhibitory evaluation of Curculigo latifolia on α-glucosidase, DPP (IV) and in vitro studies in antidiabetic with molecular docking relevance to type 2 diabetes mellitus.
المؤلفون: Zabidi NA; Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia., Ishak NA; Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.; Centre of Foundation Studies for Agricultural Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia., Hamid M; Department of Microbiology, Faculty of Biotechnology and Molecular Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia., Ashari SE; Centre of Foundation Studies for Agricultural Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.; Integrated Chemical Biophysics Research, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia., Mohammad Latif MA; Centre of Foundation Studies for Agricultural Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.; Integrated Chemical Biophysics Research, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
المصدر: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2021 Dec; Vol. 36 (1), pp. 109-121.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print Cited Medium: Internet ISSN: 1475-6374 (Electronic) Linking ISSN: 14756366 NLM ISO Abbreviation: J Enzyme Inhib Med Chem Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basingstoke, UK : Taylor & Francis, c2002-
مواضيع طبية MeSH: Curculigo/*chemistry , Diabetes Mellitus, Type 2/*drug therapy , Dipeptidyl-Peptidase IV Inhibitors/*pharmacology , Glycoside Hydrolase Inhibitors/*pharmacology , Hypoglycemic Agents/*pharmacology , Plant Extracts/*pharmacology, Animals ; Cell Survival/drug effects ; Cells, Cultured ; Diabetes Mellitus, Type 2/metabolism ; Dipeptidyl Peptidase 4/metabolism ; Dipeptidyl-Peptidase IV Inhibitors/chemistry ; Dipeptidyl-Peptidase IV Inhibitors/isolation & purification ; Dose-Response Relationship, Drug ; Fruit/chemistry ; Glycoside Hydrolase Inhibitors/chemistry ; Glycoside Hydrolase Inhibitors/isolation & purification ; Hypoglycemic Agents/chemistry ; Hypoglycemic Agents/isolation & purification ; Insulin Secretion ; Mice ; Molecular Docking Simulation ; Molecular Structure ; Plant Extracts/chemistry ; Plant Extracts/isolation & purification ; Rats ; Structure-Activity Relationship ; alpha-Glucosidases/metabolism
مستخلص: The inhibition of α-glucosidase and DPP enzymes capable of effectively reducing blood glucose level in the management of type 2 diabetes. The purpose of the present study is to evaluate the inhibitory potential of α-glucosidase and DPP (IV) activity including with the 2- NBDG uptake assay and insulin secretion activities through in vitro studies. The selected of active compounds obtained from the screening of compounds by LC-MS were docked with the targeted enzyme that involved in the mechanism of T2DM. From the results, root extracts displayed a better promising outcome in α-glucosidase (IC 50 2.72 ± 0.32) as compared with the fruit extracts (IC 50 3.87 ± 0.32). Besides, root extracts also displayed a better activity in the inhibition of DPP (IV), enhance insulin secretion and glucose uptake activity. Molecular docking results revealing that phlorizin binds strongly with α-glucosidase, DPP (IV) and Insulin receptor (IR) enzymes with achieving the lowest binding energy value. The present work suggests several of the compounds have the potential that contribute towards inhibiting α-glucosidase and DPP (IV) and thus effective in lowering post-prandial hyperglycaemia.
References: Pharmacogn Mag. 2018 Jan;13(Suppl 4):S817-S821. (PMID: 29491638)
BMC Complement Altern Med. 2017 Mar 31;17(1):181. (PMID: 28359331)
Phytomedicine. 2015 Feb 15;22(2):297-300. (PMID: 25765836)
Curr Opin Struct Biol. 2015 Apr;31:64-74. (PMID: 25845770)
Diabetes Res Clin Pract. 2018 Apr;138:271-281. (PMID: 29496507)
BMC Complement Altern Med. 2019 Mar 25;19(1):74. (PMID: 30909900)
Evid Based Complement Alternat Med. 2018 Jul 16;2018:2164345. (PMID: 30108648)
Ther Adv Chronic Dis. 2019 Sep 19;10:2040622319875305. (PMID: 31555430)
Int J Biomed Sci. 2014 Sep;10(3):208-16. (PMID: 25324703)
Molecules. 2019 Mar 27;24(7):. (PMID: 30934701)
J Diabetes Res. 2018 Jan 8;2018:5308582. (PMID: 29507862)
Nutrients. 2017 Feb 21;9(2):. (PMID: 28230764)
J Pharm Pharmacol. 2003 Jun;55(6):833-7. (PMID: 12841945)
Mol Cell Endocrinol. 2018 Jan 15;460:134-151. (PMID: 28736255)
BMC Complement Altern Med. 2015 Mar 20;15:73. (PMID: 25885803)
BMC Complement Altern Med. 2018 Apr 2;18(1):113. (PMID: 29606113)
Evid Based Complement Alternat Med. 2013;2013:601838. (PMID: 23762147)
BMC Complement Altern Med. 2014 Jun 19;14:197. (PMID: 24947113)
Sci Rep. 2018 Mar 13;8(1):4466. (PMID: 29535389)
Diabetes Res Clin Pract. 2019 Nov;157:107841. (PMID: 31518656)
Oman Med J. 2012 Jul;27(4):269-73. (PMID: 23071876)
Nutrients. 2015 Jun 15;7(6):4851-61. (PMID: 26083118)
BMC Complement Altern Med. 2011 Dec 12;11:126. (PMID: 22169757)
فهرسة مساهمة: Keywords: Curculigo latifolia; DPP (IV); molecular docking; type 2 diabetes; α-glucosidase
المشرفين على المادة: 0 (Dipeptidyl-Peptidase IV Inhibitors)
0 (Glycoside Hydrolase Inhibitors)
0 (Hypoglycemic Agents)
0 (Plant Extracts)
EC 3.2.1.20 (alpha-Glucosidases)
EC 3.4.14.5 (Dipeptidyl Peptidase 4)
تواريخ الأحداث: Date Created: 20201130 Date Completed: 20210624 Latest Revision: 20210624
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7717572
DOI: 10.1080/14756366.2020.1844680
PMID: 33249946
قاعدة البيانات: MEDLINE
الوصف
تدمد:1475-6374
DOI:10.1080/14756366.2020.1844680